scholarly journals Changes of hematological indices among patients with chronic heart failure with low ejection fraction of the left ventricle with comorbid iron deficiency

2018 ◽  
Vol 22 (4 (88)) ◽  
pp. 62-70
Author(s):  
M. O. Kolesnyk
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Left Ventricle ◽  
Ejection Fraction ◽  
Hematological Indices ◽  
Low Ejection Fraction

scholarly journals CLINICAL EXPERIENCE IN USING COMBINED FERROTHERAPY WITH L-CARNITINE IN STANDARD TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICLE EJECTION FRACTION WITH CONCOMITANT IRON DEFICIENCY ANEMIA

World Science ◽  
2019 ◽  
Vol 1 (10(50)) ◽  
pp. 37-40
Author(s):  
Valeriy P Ivanov ◽  
Mariіa O Kolesnyk ◽  
Oleg N Kolesnуk
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Left Ventricle ◽  
Ejection Fraction ◽  
Iron Deficiency Anemia ◽  
Standard Treatment ◽  
Public Health Problem ◽  
Deficiency Anemia ◽  
Global Public Health

Chronic heart failure (CHF) is a global public health problem. Despite all the technical advances available in modern cardiology, a medical strategy for the treatment of CHF has been and remains the main focus of therapeutic intervention. А particular problem is the treatment of CHF with concomitant pathology. The modern pharmacological strategy for the treatment of patients with CHF and iron deficiency anemia, except iron preparations, must take into account the use of agents that have antihypoxic, antioxidant and membrane-stabilizing effects, and at the same time regulatory effect on the metabolism of physiologically active compounds to improve the condition of patients. Therefore, this study is aimed to evaluate the effectiveness of iron deficiency anemia’s correction, identify and compare the effect of oral ferrotherapy and combined use of ferrotherapy with L-carnitine on clinical and instrumental parameters of patients with chronic heart failure with reduced ejection fraction of left ventricle as possible variants of additional therapy to standard treatment.

scholarly journals The Mediterranean Diet Benefit on Cardiovascular Hemodynamics and Erectile Function in Chronic Heart Failure Male Patients by Decoding Central and Peripheral Vessel Rheology

Nutrients ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 108
Author(s):  
Athanasios Angelis ◽  
Christina Chrysohoou ◽  
Evangelia Tzorovili ◽  
Aggeliki Laina ◽  
Panagiotis Xydis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricle ◽  
Ejection Fraction ◽  
Mediterranean Diet ◽  
Serum Prolactin ◽  
Doppler Velocity ◽  
Heart Failure Patients ◽  
Cardiovascular Hemodynamics ◽  
The Mediterranean

Background: Mediterranean diet was evaluated on erectile performance and cardiovascular hemodynamics, in chronic heart failure patients. Methods: 150 male stable heart failure patients were enrolled in the study (62 ± 10 years, New York Heart Association (NYHA) classes I–II, ejection fraction ≤40%). A detailed echocardiographic evaluation including estimation of the global longitudinal strain of the left ventricle and the systolic tissue doppler velocity of the tricuspid annulus was performed. Erectile dysfunction severity was assessed by the Sexual Health Inventory for Men-5 (SHIM-5) score. Adherence to the Mediterranean diet was evaluated by the MedDietScore. Results: The SHIM-5 score was positively correlated with the MedDietScore (p = 0.006) and augmentation index (p = 0.031) and inversely correlated with age (p = 0.002). MedDietScore was negatively associated with intima-media-thickness (p < 0.001) and serum prolactin levels (p = 0.05). Multi-adjusted analysis revealed that the inverse relation of SHIM-5 and prolactin levels remained significant only among patients with low adherence to the Mediterranean diet (p = 0.012). Conclusion: Consumption of Mediterranean diet benefits cardiovascular hemodynamics, while suppressing serum prolactin levels. Such physiology may enhance erectile ability independently of the of the left ventricle ejection fraction.

scholarly journals INFLUENCE OF IRON DEFICIENCY ON THE CLINICAL STATE AND PARAMETERS OF CENTRAL HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION

2020 ◽  
Vol 76 (4) ◽  
pp. 156-159
Author(s):  
M.P. Smirnova ◽  
◽  
P.A. Chizhov ◽  
A.A. Baranov ◽  
Y.I. Ivanova ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Ejection Fraction ◽  
Clinical Manifestations ◽  
Clinical State ◽  
Preserved Ejection Fraction ◽  
Central Hemodynamics ◽  
One Dimensional ◽  
Patients With Heart Failure

The clinical significance of iron deficiency in heart failure patients with preserved ejection fraction is not well understood. 158 patients with chronic heart failure with preserved ejection fraction were examined. The clinical manifestations of heart failure, the level of NT-proBNP, iron, ferritin, transferrin, were studied in all patients, echocardiography was performed in one-dimensional, two-dimensional, and Doppler modes (pulse-wave, constant-wave, and tissue) in standard positions according to the generally accepted technique. It has been established that iron deficiency in patients with heart failure with preserved ejection fraction worsens the indices of central hemodynamics and promotes an increase in the clinical manifestations of heart failure, especially in the development of anemia.

scholarly journals PERORAL FERROCORRECTION OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION

2019 ◽  
Vol 19 (3) ◽  
pp. 31-36
Author(s):  
V. P. Ivanov ◽  
M. O. Kolesnyk ◽  
O. M. Kolesnуk
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Iron Deficiency ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Latent Iron Deficiency ◽  
Per Oral

Therapy of iron deficiency as a common comorbidity in chronic heart failure is being paid much attention. It plays contributory role in the morbidity and mortality of heart failure. However, there are some questions requiring future research to answer them. Nowadays, the parenteral administration of iron supplements has been considered as one of the effective approaches for the correction of the above-mentioned disorders, although per oral rout of ferrum administration is playing the leading role. Among the disputable questions there is duration of peroral ferrocorrection course for patients with latent iron deficiency. Taking into account some disadvantages of per oral ferrocorrection, e.g. slow absorption in the gastrointestinal tract or reduced absorption in conditions of even minimal inflammation or blood congestion, in order to improve the condition of the patients with chronic heart failure and concomitant latent iron deficiency, we decided to prolong the course of therapy in our study. The purpose of the study was to determine the effectiveness of 6-month per oral ferrotherapy in patients with heart failure with reduced left ventricular ejection fraction and concomitant latent iron deficiency. Material and methods. We examined 60 patients, 41 (68.3%) men and 19 (37.1%) women, aged 68.3 ± 0.63 years with chronic heart failure with reduced left ventricular ejection fraction functional class II-III according to NYHA, who were also diagnosed to have concomitant latent iron deficiency. Two study groups were formed: the patients of the 1st group (n=30) received only the standard therapy for chronic heart failure according to the European recommendations (2016); the patients of the 2nd group (n=30) were prescribed to take ferrous sulphate per orally in a dose of 320 mg, equivalent to 100 mg of bivalent iron and 60 mg of ascorbic acid 2 tablets per day for 6 months. Results and discussion. By the study’s end, anaemia was observed in 76.5% of patients. However, among these patients, 84.6% had latent iron deficiency and only 15.4% had complete cure of the iron deficiency. Thus, it was found out that without supportive therapy with iron medicines for 32.8±0.7 months after the end of iron deficiency, patients with chronic heart failure had negative laboratory dynamics. Analysis of the dynamics of haematological indices as markers of the ferrocorrection effectiveness in the patients who received the 6-month ferrotherapy demonstrated an increase of all parameters and normalization of iron metabolism indices. Moreover, 96.7% of the patients, who took standard therapy and ferrum medicines, demonstrated the elimination of iron deficiency signs. Conclusion. Thus, the study showed that per oral therapy with iron sulphate at the stage of latent iron deficiency in patients with heart failure with reduced left ventricular ejection fraction for a period of 6 months has been found out as effective.

scholarly journals Effect of ferrotherapy on clinical and instrumental indices in patients with chronic heart failure with reduced left ventricular ejection fraction and concomitant latent iron deficiency

2019 ◽  
Vol 23 (3) ◽  
pp. 382-388
Author(s):  
V.P. Ivanov ◽  
M.O. Kolesnyk ◽  
O.M. Kolesnуk
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Ejection Fraction ◽  
Stress Test ◽  
Transferrin Saturation ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Latent Iron Deficiency

The objective of the study was to assess changes of clinical and instrumental indices in patients with chronic heart failure (CHF) with reduced left ventricular (LV) ejection fraction (EF) and concomitant latent iron deficiency (ID) on the background of the standard treatment in combination with 6-months oral ferrotherapy. 60 patients with CHF with reduced LV EF functional class (FC) II-III according to NYHA with concomitant latent ID were examined. Among them were 41 (68.3%) men and 19 (37.1%) women aged 68.3±0.63 years. Two groups of patients with CHF and latent iron deficiency were formed: the 1st group (n=30) received a standard therapy, the patients in the 2nd group (n=30) were additionally prescribed oral ferrous sulfate in a dose of 320 mg, equivalent to 100 mg of bivalent iron and 60 mg of ascorbic acid per day for 6 months. Number of red blood cells (Rbc), hemoglobin (Hb) level, serum iron (SI), ferritin, transferrin saturation (ТS), 6-minute walk stress test (6MWT), MLHFQ and MOS SF36 questionnaire and LV morpho-functional parameters by echocardiography were determined. The studied values are presented as a median (upper, lower quartile). After the therapy the values of Hb, Rbc, SI, ferritin and TS have significantly increased in the 2nd group. But in the 1st group due to the lack of ferrocorrection, in most cases, the values have reduced. An increase of the covered 6MWT distance, MLHFQ points, physical (PH) and mental (MH) components of health of MOS SF36 was observed in both groups: in the first group only by 5.3 (р=0.06), 1.2 (р=0.46), 6.9 (р=0.31) and 7.2% (р=0.02), respectively. Whereas in the second group by 13.8 (p<0.001), 13.6 (p<0.001), 24% (p<0.001) and 15% (p<0.001), respectively. EDD (end-diastolic dimension) decreased by 2.1% (p<0.001), EDV (end-diastolic volume) — by 4.8% (p<0.001), ESD (end-systolic dimension) — by 3.9% (p<0.001), ESV (end-systolic volume) — by 13.3% (p<0.0001), EF has increased by 12.7% (p<0.001) in the first group. No difference in the dynamics of the Echo-CG indices between two groups of patients over 6 months of observation was detected (р>0.18). EDD decreased by 2.7% (p<0.001), EDV — by 3.9% (p<0.0001), ESD — by 3.9%, ESV — by 10.9% (p<0.0001), EF has increased by 16.3% (p<0.0001).Thus, the positive hematological changes in case of latent ID correction in patients with CHF with reduced LV EF, despite the similar dynamics of myocardium morpho-functional indices in case of absent ferrocorrection, are accompanied by more significant positive dynamics of effort tolerance and quality of life.

Sign in / Sign up

Export Citation Format

Share Document